Myeloablative chemotherapy and stem cell transplantation in myeloma or primary amyloidosis with renal involvement

Kidney Int. 2005 Oct;68(4):1464-71. doi: 10.1111/j.1523-1755.2005.00559.x.

Abstract

Background: High-dose chemotherapy and stem cell transplantation are being applied increasingly to the treatment of selected patients with multiple myeloma or primary systemic amyloidosis. Stem cell transplantation presents unique challenges to the nephrologist because of the high prevalence of renal involvement in myeloma and the issues that are associated with high-dose chemotherapy in patients with the nephrotic syndrome due to renal amyloid.

Methods: We review the published literature on stem cell transplantation in patients with reduced renal function.

Results and conclusions: The specifics of transplantation pertaining to patients with renal amyloid nephrotic syndrome are discussed in detail.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Amyloidosis / complications
  • Amyloidosis / therapy*
  • Hematopoietic Stem Cell Transplantation*
  • Humans
  • Multiple Myeloma / complications
  • Multiple Myeloma / therapy*
  • Myeloablative Agonists / therapeutic use*
  • Nephrotic Syndrome / etiology
  • Nephrotic Syndrome / therapy*

Substances

  • Myeloablative Agonists